Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30368% above fair value
$28.26+0.73 (+2.65%)
Close on Nov 13, 2026Market cap $3.55BP/E 128.5Yield –
Arcutis Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Arcutis Biotherapeutics's operating margin for the twelve months ending Sep 30, 2026 was 6.9%. For fiscal 2025 it was -3.3%, against -65.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3.3% | +62.1 |
| FY2024 | Dec 31, 2024 | -65.3% | +339.2 |
| FY2023 | Dec 31, 2023 | -404.5% | +7778.6 |
| FY2022 | Dec 31, 2022 | -8183.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 6.6% | −2.0 |
| Q2 FY2026 | Jun 30, 2026 | 12.7% | +30.6 |
| Q1 FY2026 | Mar 31, 2026 | -8.6% | +28.6 |
| Q4 FY2025 | Dec 31, 2025 | 14.2% | +24.9 |
| Q3 FY2025 | Sep 30, 2025 | 8.6% | +95.9 |
| Q2 FY2025 | Jun 30, 2025 | -17.9% | +144.4 |
| Q1 FY2025 | Mar 31, 2025 | -37.3% | +26.5 |
| Q4 FY2024 | Dec 31, 2024 | -10.7% | +441.5 |
| Q3 FY2024 | Sep 30, 2024 | -87.3% | +9.5 |
| Q2 FY2024 | Jun 30, 2024 | -162.3% | +1124.1 |
| Q1 FY2024 | Mar 31, 2024 | -63.8% | +2678.6 |
| Q4 FY2023 | Dec 31, 2023 | -452.2% | +1858.6 |
| Q3 FY2023 | Sep 30, 2023 | -96.8% | +14351.2 |
| Q2 FY2023 | Jun 30, 2023 | -1286.4% | – |
| Q1 FY2023 | Mar 31, 2023 | -2742.4% | – |
| Q4 FY2022 | Dec 31, 2022 | -2310.8% | – |
| Q3 FY2022 | Sep 30, 2022 | -14448.0% | – |
See a number that looks wrong?